A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1133 participants.
Also called NCT06778967
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,133 participants
- Sponsor
- Registry
-
NCT06778967
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06778967. Randomized; no masking; primary purpose treatment. Start 2025-02-13 (actual); primary completion 2026-09-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
- Acronym
- Optimum 2
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- GZR18
- Intervention (Drug)
- semaglutide
- Lead sponsor
- Gan & Lee Pharmaceuticals.
Record details
- Record id
cardio:ct-nct06778967- Content hash
337c1631d380b7312a524723ccfcd234a8ff67c65d9eb95f76ddebaf5502a76f